TIRZEP
Tirzepatide is an investigational synthetic peptide that functions as a dual receptor agonist, targeting both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This peptide is provided in liquid form with a purity level of ≥99%, making it suitable for in-vitro and laboratory research applications.
$124.99 – $324.99
Overview
Tirzepatide is currently under investigation for its wide-ranging effects on metabolic disorders. Its unique mechanism of action, combining GIP and GLP-1 receptor activation, offers a promising research avenue into obesity, diabetes, and metabolic syndrome.
Product Research
-
Type 2 Diabetes and Glycemic Control
In a randomized phase 3 trial, tirzepatide demonstrated superior reduction in HbA1c levels compared to semaglutide, highlighting its potential role in glycemic control models for type 2 diabetes research [1].
-
Obesity and Weight Management
A 72-week phase 3 clinical study found that individuals treated with tirzepatide experienced substantial reductions in body weight, with greater efficacy than existing GLP-1 receptor agonists [2].
-
Non-Alcoholic Steatohepatitis (NASH)
In a phase 2 trial involving participants with metabolic dysfunction-associated steatohepatitis (MASH), tirzepatide was associated with resolution of MASH without worsening of fibrosis, suggesting potential relevance in liver-related metabolic research [3].
-
Cardiovascular Health
Early data from cardiovascular outcome studies indicate that tirzepatide may support improvements in lipid profiles, blood pressure, and systemic inflammation—all key markers in cardiovascular disease models [4].
-
Beta-Cell Function and Insulin Sensitivity
Preclinical and clinical research suggests that tirzepatide enhances beta-cell function and insulin sensitivity, critical for modeling pancreatic health and long-term glucose regulation [5].
Disclaimer
This product is intended for laboratory research and development purposes only. It is not approved for human consumption, medical, or veterinary use. All content provided is strictly for informational and educational purposes relating to laboratory research. Product must be handled only by qualified professionals under appropriate laboratory conditions.
Referenced Citations
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes – New England Journal of Medicine
- Tirzepatide once weekly for the treatment of obesity – New England Journal of Medicine
- Tirzepatide in adults with MASH: a phase 2 trial – New England Journal of Medicine
- Cardiometabolic risk reduction with tirzepatide – The Lancet Diabetes & Endocrinology
- Tirzepatide improves β-cell function and insulin sensitivity – Diabetes Care
Related Products
Overview
Tirzepatide is currently under investigation for its wide-ranging effects on metabolic disorders. Its unique mechanism of action, combining GIP and GLP-1 receptor activation, offers a promising research avenue into obesity, diabetes, and metabolic syndrome.
Product Research
-
Type 2 Diabetes and Glycemic Control
In a randomized phase 3 trial, tirzepatide demonstrated superior reduction in HbA1c levels compared to semaglutide, highlighting its potential role in glycemic control models for type 2 diabetes research [1].
-
Obesity and Weight Management
A 72-week phase 3 clinical study found that individuals treated with tirzepatide experienced substantial reductions in body weight, with greater efficacy than existing GLP-1 receptor agonists [2].
-
Non-Alcoholic Steatohepatitis (NASH)
In a phase 2 trial involving participants with metabolic dysfunction-associated steatohepatitis (MASH), tirzepatide was associated with resolution of MASH without worsening of fibrosis, suggesting potential relevance in liver-related metabolic research [3].
-
Cardiovascular Health
Early data from cardiovascular outcome studies indicate that tirzepatide may support improvements in lipid profiles, blood pressure, and systemic inflammation—all key markers in cardiovascular disease models [4].
-
Beta-Cell Function and Insulin Sensitivity
Preclinical and clinical research suggests that tirzepatide enhances beta-cell function and insulin sensitivity, critical for modeling pancreatic health and long-term glucose regulation [5].
Disclaimer
This product is intended for laboratory research and development purposes only. It is not approved for human consumption, medical, or veterinary use. All content provided is strictly for informational and educational purposes relating to laboratory research. Product must be handled only by qualified professionals under appropriate laboratory conditions.
Referenced Citations
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes – New England Journal of Medicine
- Tirzepatide once weekly for the treatment of obesity – New England Journal of Medicine
- Tirzepatide in adults with MASH: a phase 2 trial – New England Journal of Medicine
- Cardiometabolic risk reduction with tirzepatide – The Lancet Diabetes & Endocrinology
- Tirzepatide improves β-cell function and insulin sensitivity – Diabetes Care
| Size | 5MG, 10MG, 15MG |
|---|
Reviews
There are no reviews yet.